Jones Financial Companies
OTLK icon

Jones Financial Companies’s Outlook Therapeutics OTLK Stock Holding History

Jones Financial Companies’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.28K Hold
2,500
– – ﹤0.01% 4170
2026
Q1 		$520 Hold
2,500
– – ﹤0.01% 4482
2025
Q4 		$3.95K Hold
2,500
– – ﹤0.01% 3594
2025
Q3 		$2.42K Buy
+2,500
New +$4.32K ﹤0.01% 3626

Other funds holding OTLK

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
GWM
Gilpin Wealth Management Denver, Colorado $145M AUM

Jones Financial Companies's OTLK Position: Q2 2026 in Review

Jones Financial Companies held its Outlook Therapeutics (OTLK) position steady in Q2 2026 at 2,500 shares worth $4.28K. The position accounts for ﹤0.01% of the portfolio, ranked #4170.

Jones Financial Companies first reported a position in OTLK in Q3 2025 and has held it in 4 quarters since. 70 funds tracked by Wall St. Rank hold OTLK as of Q2 2026.

  • Jones Financial Companies held 2,500 shares of Outlook Therapeutics worth $4.28K as of Q2 2026.
  • Jones Financial Companies left its Outlook Therapeutics share count unchanged in Q2 2026.
  • Outlook Therapeutics made up ﹤0.01% of Jones Financial Companies's portfolio in Q2 2026, its #4170 holding.
  • Jones Financial Companies first reported a position in Outlook Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 70 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q2 2026.

Based on Jones Financial Companies's 13F filing for Q2 2026, filed 14 Aug 2026.